This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the US in January. As ...
The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
The landscape of oncology nursing has undergone a seismic shift in safety protocols over the last two decades. In the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results